Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Acta Interna : The Journal of Internal Medicine Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Medical Journal of Indonesia Mutiara Medika: Jurnal Kedokteran dan Kesehatan Jurnal Gizi Klinik Indonesia
Johan Kurnianda
Division Of Hematology And Medical Oncology, Department Of Internal Medicine, Faculty Of Medicine, Universitas Gadjah Mada / Dr. Sardjito Hospital Yogyakarta
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 25 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search
Journal : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

 1 
Secondary acute myeloblastic leukemia after adjuvant chemotherapy and radiotherapy in breast cancer: A case report Hardianti, Mardiah Suci; Kurnianda, Johan; Taroeno-Hariadi, Kartika Widayati
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 46, No 03 (2014)
Publisher : Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (131.544 KB) | DOI: 10.19106/JMedScie004603201405

Abstract

A rising number of long-term survivors and potential long-term outcome related to the treatment isone of the most important issue due to the advances of management in cancer. The development ofsecondary malignancy has been reported in a number of cohorts. We present a case of breast cancerpatient developing acute myeloid leukemia (AML)- M5 within a relatively short interval of two and ahalf years from her primary treatment with adjuvant chemotherapy with 4 cycles of doxorubicin andcyclophosphamide, followed by 4 cycles of three weekly paclitaxel (AC-T) and radiotherapy. Whatcould be attributed to the occurrence of secondary leukemia in this patient will be discussed.
Secondary acute myeloblastic leukemia after adjuvant chemotherapy and radiotherapy in breast cancer: A case report Mardiah Suci Hardianti; Johan Kurnianda; Kartika Widayati Taroeno-Hariadi
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 46, No 03 (2014)
Publisher : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (131.544 KB) | DOI: 10.19106/JMedScie004603201405

Abstract

A rising number of long-term survivors and potential long-term outcome related to the treatment isone of the most important issue due to the advances of management in cancer. The development ofsecondary malignancy has been reported in a number of cohorts. We present a case of breast cancerpatient developing acute myeloid leukemia (AML)- M5 within a relatively short interval of two and ahalf years from her primary treatment with adjuvant chemotherapy with 4 cycles of doxorubicin andcyclophosphamide, followed by 4 cycles of three weekly paclitaxel (AC-T) and radiotherapy. Whatcould be attributed to the occurrence of secondary leukemia in this patient will be discussed.
Diffuse Large B-Cell Lymphoma Complicated by Small Bowel Obstruction after Radiotherapy: a Case Study Diah Ari Safitri; Kartika Widayati Taroeno-Hariadi; Johan Kurnianda; Ibnu Purwanto
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 48, No 3 (2016)
Publisher : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (15.012 KB) | DOI: 10.19106/JMedSci004803201606

Abstract

ABSTRACTAlthough the spleen is frequently involved in disseminated non-Hodgkin’s lymphoma (NHL), splenic presentation as the initial or only site of disease is uncommon. Treatment modalities include surgery, chemotherapy, and radiation therapy. The priority of cancer follow up is to perform surveillance for recurrent cancer and evaluation of treatment response. Side effects of treatment are frequently missed or overlooked. A 66-year-old woman was presented to our hospital with a month history of spleen enlargement. On physical examination the spleen was palpated at Schuffner 2. Abdominal MSCT scan was suggestive of lymphoma. Surgery revealed adhesion and obstruction of the stomach. Biopsy and gastrojejunostomy shunting were done, but splenectomy was difficult. The pathology anatomy findings confirmed the diagnosis of diffuse non Hodgkin’s lymphoma large B-cell type. Immunohistochemistry showed positive CD3 and CD20. She underwent 6 cycles of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone (RCHOP) chemotherapy. CT evaluation done 7 months later revealed that the hilus lienalis lymph nodes and spleen has decrease in size. However, a lumbosacral x-ray done due to back pain revealed metastasis on her 1st and 2nd lumbal spine. After a single fraction of radiotherapy, nausea, vomiting and abdominal distension occurred. A 3 position abdominal x-ray revealed signs of small bowel obstruction. After surgery she has received 9 cycles of zoledronic acid and remained in good condition and ambulatory. Splenic presentation as the initial or only site of non-Hodgkin’s lymphoma (NHL) is uncommon. Acute small bowel obstruction and fistula due to palliative radiation therapy for bone metastasis needs prompt and appropriate treatment.
Convalescent plasma for COVID-19: A reasonable option for the pandemic based on both scientific and practical point of views Mardiah Suci Hardianti; Syahru Agung Setiawan; David Dwi Putera; Teguh Triyono; Jarir At Thobari; Johan Kurnianda
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 52, No 3 (2020): Special Issue: COVID-19
Publisher : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (171.687 KB) | DOI: 10.19106/JMedSciSI005203202011

Abstract

Convalescent plasma treatment has become a promising adjunctive option to treat COVID-19. Several case reports consistently supported the feasibility of this approach by showing the safety and improvements of clinical and laboratory aspects from the treated patients. However, more clinical trials are still required to establish the definitive statement about its potential effectiveness. We review the scientific basis for the application of convalescent plasma in COVID-19 to understand its potentials better. We also cover the potential risks and benefits for this treatment in order to be more selective and careful when preparing and deciding to apply this approach. Lastly, we summarize any important points to monitor after the administration of this treatment to prioritize safety and measure the effectiveness of the treatment.
Co-Authors A. Harijadi Agus Siswanto Astuti, Herni David Dwi Putera Diah Ari Safitri Dwi Rohmawati Dwi Wulansih Eiji Tatsumi Ganda Hidayat Herni Astuti Hiroyuki Sakoda I Dewa Putu Pramantara I Dewa Putu Pramantara I Ketut Suada I Wayan Dwija Karyasa Ibnu Purwanto Jamhari Jamhari Jarir At Thobari Kaho Furuta Kartika W. Taroeno-Hariadi Kartika Widayati Taroeno Hariadi Karyasa, I Wayan Dwija Katsuyasu Saigo Kayoko Masuda Ken-Ichi Nagai Mardiah Suci Hardianti Meilani Syampurnawati Muhammad Ihsan Qomaruzzaman Nina Mulyani Noor Asyiqah Sofia Nugroho Wiyadi Prafita Cahya Dewanti Puntodewo Puntodewo Qomaruzzaman, Muhammad Ihsan Sagiri Mangunsudirjo Seiji Kawano Selvyana, Dita Ria Setsuki Isono Shin-Ichi Kondo Shunichi Kumagai Sofia M. Haryana Sukendro Sendjaja Susetyowati Syahru Agung Setiawan Takayuki Takahashi Teguh Triyono Wahyu Wulaningsih Yenita . Yenita Yenita Yoshitaka Hayashi